Retire? Bill Chin’s tried it three times, and he’d rather be working at Frequency Therapeutics
William Chin’s resume sprints through 25 years of prestigious posts: Harvard professor, a senior VP of global research at Eli Lilly, back to Harvard as executive dean for research, then on to PhRMA as their head of science and regulatory affairs.
Now he’s going to a small biotech in Woburn, MA which is trying to do some breakthrough work on the 2.0 version of regenerative medicine.
Why?
The simple answer, he tells me, starts when he stepped down from PhRMA at the beginning of this year. It was his third retirement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
